COGNICURRENT

Jan 8 • 00:30 UTC • 🇨🇳 China • South China Morning Post

Chinese drug makers strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers achieved a historic US$136 billion in out-licensing agreements in 2025, more than doubling the previous year's total with 157 deals signed.

#china #pharmaceuticals #licensing #out-licensing #deals

Read Original Back to Feed

📡 Similar Coverage

🇨🇳 China Mar 4 • 09:30 UTC

China biotech outlicensing tops US$52 billion in first 2 months after global deal surge

South China Morning Post

🇨🇳 China Mar 1 • 04:00 UTC

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals

South China Morning Post

🇨🇳 China Mar 20 • 06:30 UTC

Global drug giants double down on China amid trend to build self-reliant supply chains

South China Morning Post

🇨🇳 China Feb 10 • 05:00 UTC

Chinese investors pour into Hong Kong-listed drug stocks as international deals multiply

South China Morning Post

🇨🇳 China Feb 6 • 09:00 UTC

Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships

South China Morning Post

🇨🇳 China Mar 17 • 11:48 UTC

US reshoring drive casts shadow over China’s contract drug makers: analyst

South China Morning Post